Related Experiment Videos
Reinduction chemotherapy in small cell lung cancer
G Giaccone1, P Ferrati, M Donadio
1Division of Medical Oncology, Ospedale S. Giovanni, Torino, Italy.
European Journal of Cancer & Clinical Oncology
|November 1, 1987
Summary
Retreating small cell lung cancer patients with the same chemotherapy regimen after relapse can lead to significant responses and improved survival. This approach is effective when initial chemotherapy was successful and short-lived.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Small cell lung cancer (SCLC) often relapses after initial chemotherapy.
- Effective retreatment strategies for relapsed SCLC are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of re-administering the same chemotherapy regimen in patients with relapsed SCLC.
- To assess the impact of this retreatment strategy on patient survival.
Main Methods:
- Retrospective analysis of 13 SCLC patients who received the same chemotherapy at relapse.
- Patients had previously responded to the initial regimen, with a median 30-week off-therapy interval.
Main Results:
- 50% of patients responded to reinduction chemotherapy.
- Two of six patients achieving complete response initially also achieved complete response upon retreatment.
- Median survival from the start of any therapy was 94 weeks.
Conclusions:
- Re-challenging with the same chemotherapy regimen is a viable strategy for relapsed SCLC patients.
- This approach shows promise for improving survival in patients with relapsed SCLC, particularly when initial therapy was effective and brief.